Ambarella Introduces CV5 High Performance AI Vision Processor for Single 8K and Multi-Imager AI Cameras
11.1.2021 13:00:00 EET | Business Wire | Press release
Ambarella, Inc. (Nasdaq: AMBA), an AI vision silicon company, today unveiled CV5, an artificial intelligence (AI) vision processor capable of recording 8K video or four 4K video streams. The new system on chip (SoC) will enable the development of intelligent automotive camera systems, consumer cameras (drone, action, and 360°), and robotic cameras. It combines Ambarella’s powerful CVflow AI engine with dual Arm® A76 CPUs to provide the performance necessary for a wide range of AI-based algorithms. Its advanced image signal processor (ISP) can simultaneously process images for both human viewing and machine processing. Fabricated in advanced 5 nm process technology, CV5 consumes under 2 watts of power while encoding full 8K video at 30 frames per second.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005235/en/
Ambarella today unveiled the CV5 AI vision CVflow® 5 nm processor for single 8K and multi-imager AI cameras, setting a new standard for power efficiency with 8K video recording in under 2 watts. The SoC targets intelligent automotive camera systems, consumer cameras (drone, action, and 360°), and robotic cameras. (Photo: Business Wire)
“With the introduction of CV5, Ambarella is defining the next generation of automotive, consumer, and robotic cameras,” said Fermi Wang, CEO of Ambarella. “By combining 8K single-channel and 4K multi-channel recording with the high performance of our CVflow AI engine, we are enabling cameras with the highest-quality imaging and innovative new AI features.”
In automotive video telematics applications, CV5 provides the performance necessary to encode multiple video streams from front ADAS, driver monitoring, cabin monitoring, and side-view cameras. Its CVflow AI engine can simultaneously run advanced driver assistance systems (ADAS) algorithms such as lane departure, and forward collision warning as well as driver monitoring algorithms such as drowsy driver detection. The combination of high-resolution video capture with advanced AI processing enables ADAS cameras to recognize images over long distances and with high accuracy.
The exceptionally low power consumption of the CV5 SoC also makes it an ideal solution for the next generation of high resolution and high frame-rate action, 360°, and virtual reality (VR) cameras, offering 8K recording and playback in very small form factor designs.
In robotic and drone applications, CV5’s CVflow AI engine can accelerate simultaneous localization and mapping (SLAM), path planning, and obstacle detection, and avoidance algorithms for navigation and autonomous operation. For drone-based aerial videography and cinematography, CV5 can simultaneously perform flight control and navigation functions while recording up to 8K resolution video recording at 60 frames per second.
The CV5 SoC shares common SDK and computer vision (CV) tools with Ambarella’s other CVflow SoC families, simplifying development of cameras with multiple price and performance options. A complete set of CV tools helps customers port their own neural networks onto CV5, including a compiler, debugger, and support for industry-standard machine learning frameworks, such as PyTorch™, ONNX™, Caffe™, and TensorFlow™, as well as extensive guidelines for convolutional neural network (CNN) performance optimization.
CV5 SoC key features:
- CVflow architecture with DNN support
- Dual-core Arm® Cortex®-A76 up to 1.6 GHz with NEON™ DSP extensions and FPU
- High-speed SLVS-EC, MIPI-CSI (C/D PHY) interfaces, connecting up to 14 cameras
- Multi-channel ISP with up to 8KP60 throughput
- Native support for RGGB, RCCB, RCCC, RGB-IR, and monochrome sensor formats
- Multi-exposure high dynamic range (HDR) processing
- Real-time, hardware-accelerated fisheye dewarping and lens distortion correction (LDC)
- AVC and HEVC encoding with up to 8KP60 throughput and multiple stream support
- Rich set of interfaces includes 4-lane PCIe, CAN FD, Gigabit Ethernet, USB 3.1 host and device, three SD card controllers, MIPI DSI/CSI-2 and HDMI video outputs
- LPDDR4x / LPDDR5 / LPDDR5x support, 64-bit data bus and up to 32 GB capacity
- Advanced security features, including secure boot with TrustZone® and secure memory, TRNG, OTP, DRAM scrambling and virtualization
- 5 nm process technology
- 16x16 FBGA package with 0.5 mm ball pitch
About Ambarella, Inc.
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. © 2021 Ambarella, Inc. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005235/en/
Contact information
Ambarella Contact: www.ambarella.com/about/contact/inquiries
Media Contact: Molly McCarthy, Valley Public Relations, mmccarthy@ambarella.com
Investor Relations Contact: Louis Gerhardy, Ambarella, lgerhardy@ambarella.com, (408) 636-2310
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 17:00:00 EEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 16:30:00 EEST | Press release
Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country. The funding will advance Project Obsidian, the world's first commercial superhot geothermal power plant, in Central Oregon. It will support analysis of the drilling, stimulation, and flow results of the first two wells to optimize a third well at the Obsidian site. The three-well configuration is targeting average reservoir temperatures of over 300°C and is designed to demonstrate more than 25 megawatts of gross electric power capacity. The DOE funding will also enable Qu
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 16:00:00 EEST | Press release
Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and their families access care, adopt healthier habits, and improve long-term oral health outcomes. “At Colgate-Palmolive, we believe oral health and healthier, brighter futures are inextricably link
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 15:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
